<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>investing on Christopher Gandrud â„ˆ</title>
    <link>https://dazzling-roentgen-3e71e9.netlify.app/tags/investing/</link>
    <description>Recent content in investing on Christopher Gandrud â„ˆ</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en</language>
    <copyright>Â© 2020, Christopher Gandrud</copyright>
    <lastBuildDate>Sat, 16 May 2020 00:00:00 +0000</lastBuildDate>
    
	<atom:link href="https://dazzling-roentgen-3e71e9.netlify.app/tags/investing/index.xml" rel="self" type="application/rss+xml" />
    
    
    <item>
      <title>Two extremes of ðŸ§ªscientific investment and innovation: Genentech and Theranos</title>
      <link>https://dazzling-roentgen-3e71e9.netlify.app/post/two-extremes-of-scientific-investment-and-innovation-genentech-and-theranos/</link>
      <pubDate>Sat, 16 May 2020 00:00:00 +0000</pubDate>
      
      <guid>https://dazzling-roentgen-3e71e9.netlify.app/post/two-extremes-of-scientific-investment-and-innovation-genentech-and-theranos/</guid>
      <description>The contrast How can we successfully pair capital and research to produce genuine innovations that bring real value to many people? Two silicon valley biotech companies with very different trajectories highlight some factors that may be involved. The two companies are Genentech and Theranos.
Both venture-capital-funded companies started in silicon valley with the aim to create valuable products based on new scientific research. Founded in 1976, Genentech has been enduringly successful since its first breakthrough in 1982 when it created synthetic insulin, the first genetically engineered human therapeutic.</description>
    </item>
    
  </channel>
</rss>